DEA Reiterates Stance That Lab-Derived Cannabinoids Are Not Compliant With the Farm Bill
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchHempIndustry Why This Matters Clinicians need to understand that synthetic cannabinoids derived from…
Congressional Report Explains Implications—And Limitations—Of Trump’s … – Marijuana Moment
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyHempCBD Clinical Summary # Clinical Summary This congressional report addresses recent legislative developments…
DOJ Reschedules Medical Marijuana: What It Means for Insurance Coverage
The DOJ's rescheduling of medical marijuana has significant medical marijuana insurance coverage implications. This change may increase insurance reimbursement options and reduce patient costs. Clinicians can now better guide patients on accessing…
Medical Marijuana Reclassification: New Research Opportunities – Observer Voice
Cannabis reclassification medical research is opening new doors for rigorous clinical studies on therapeutic efficacy and safety. This shift reduces federal barriers, enabling better evidence generation. Clinicians can now anticipate improved guidelines…
Should marijuana access be expanded? On April 23, 2026, the Trump administration … – Facebook
✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchMedical MarijuanaMental Health Clinical Summary The Trump administration’s April 2026 policy…
The Biggest Things About Schedule III You Haven’t Thought Of | Cannabis Business Times
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustry Clinical Summary # Clinical Summary The potential rescheduling of cannabis from Schedule I to…
Federal marijuana reclassification could reshape medical research and cannabis industry
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustryAging Clinical Summary The potential federal reclassification of marijuana from Schedule I to a…
Justice Department, DEA ordered to reclassify state-licensed medical cannabis as less … – Maui Now
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchSafety Clinical Summary A federal court has ordered the Department of Justice and DEA to reclassify…
Group Seeks Court Order to Halt CMS Medicare THC Hemp Marijuana Program
The CMS hemp pilot lawsuit highlights a legal challenge affecting Medicare cannabinoid coverage. This case could reshape access to cannabis-derived products for Medicare patients. Clinicians should monitor this lawsuit closely due to its impact on…
Trump Administration Reclassifies Cannabis: Impact on Medical Research
The federal cannabis reclassification medical research shift could accelerate clinical trials and improve evidence-based prescribing. This policy change removes barriers to studying cannabis's therapeutic potential. Clinicians should monitor emerging…